Highlights Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
20.12 ^USD	-4.33%		-0.05%	-26.86%

05-07	Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	MT
05-07	Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	05-07	MT
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024	05-07	CI
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M	02-22	MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	02-22	CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Veracyte Closes $70 Million C2i Genomics Acquisition	02-06	MT
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc.	02-04	CI
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023	01-08	CI
Veracyte, Inc. has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.	01-07	CI
Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook	11-08	MT
Earnings Flash (VCYT) VERACYTE Reports Q3 Revenue $90.1M, vs. Street Est of $84.4M	11-07	MT
Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023	11-07	CI
Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer	23-10-04	CI
Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer	23-09-28	CI
Veracyte, Inc. and Gustave Roussy Announces Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies	23-09-06	CI
Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer	23-08-22	CI
Veracyte Q2 Loss Narrows, Revenue Increases; Raises 2023 Revenue Guidance	23-08-09	MT
Earnings Flash (VCYT) VERACYTE Reports Q2 Revenue $90.3M, vs. Street Est of $83.1M	23-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Veracyte, Inc.

Equities

VCYT

US92337F1075

Highlights

Filters